Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histamine SCHEMBL123244 | 1.00 | HRH4 (0.35) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL9317522 | 1.00 | HRH4 (0.35) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL2407943 | 1.00 | HRH4 (0.35) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL8720072 | 1.00 | HRH4 (0.35) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL28152485 | 0.98 | HRH4 (0.34) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL2058267 | 0.98 | HRH4 (0.34) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL28942413 | 0.98 | HRH4 (0.34) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Histamine SCHEMBL29175699 | 0.96 | HRH1 (0.35) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| P-Xylene SCHEMBL28101363 | 0.91 | TAAR1 (0.38) | HRH4HRH3CYP2C9TSHRCYP2C19 | |
| Pyrophosphoric Acid SCHEMBL2113037 | 0.90 | TDP1 (0.32) | HRH4HRH3CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294446-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | Agonex Biopharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| CN-117241830-A | Systems, devices and formulations for time-phased histamine delivery | 阿戈纳克斯生物制药公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230390215-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | AGONEX BIOPHARMACEUTICALS, INC. | 2023-12-07 | — | — | US | claimed |
| US-20230241029-A1 | METHODS OF REDUCING POST-SURGICAL METASTASIS | HELLSTRAND KRISTOFFER (SE) | 2023-08-03 | — | — | US | claimed |
| WO-2022178120-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | AGONEX BIOPHARMACEUTICALS, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20210187072-A1 | METHODS AND COMPOSITIONS FOR REDUCING RISK OF RELAPSE AND PROLONGING SURVIVAL IN ACUTE MYELOID LEUKEMIA | MARTNER ANNA (SE) | 2021-06-24 | — | — | US | claimed |
| EP-3796911-A2 | METHODS AND COMPOSITIONS FOR REDUCING RISK OF RELAPSE AND PROLONGING SURVIVAL IN ACUTE MYELOID LEUKEMIA | Martner, Anna (SE) | 2021-03-31 | — | — | EP | claimed |
| CN-112423753-A | Methods and compositions for reducing the risk of relapse and prolonging survival of acute myeloid leukemia | A·马特内尔 | 2021-02-26 | — | — | CN | claimed |
| US-20200399642-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING METASTATIC TUMORS | Immune pharmaceuticals inc (US) | 2020-12-24 | — | — | US | claimed |
| US-20200222505-A1 | METHODS OF DELAYING AND PREVENTING ACUTE MYELOID LEUKEMIA RELAPSE | Immune pharmaceuticals inc (US) | 2020-07-16 | — | — | US | claimed |
| WO-2003039418-A1 | COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS DISEASES | MAXIM PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20020095001-A1 | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors | GEHLSEN KURT R (US) | 2002-07-18 | — | — | US | claimed |
| CN-1342076-A | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors | MAXIM PHARMACEUTICAL INC (US) | 2002-03-27 | — | — | CN | claimed |
| US-6350785-B2 | ADMINISTERING HISTAMINE TO TREAT SKIN DISORDERS; FREE RADICAL SCAVANGERS | MAXIM PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | claimed |
| EP-1143969-A1 | METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS | Maxim Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000040240-A9 | METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS | MAXIM PHARMACEUTICAL INC (US) | 2001-10-04 | — | — | WO | claimed |
| US-20010018059-A1 | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors | CYTOVIA, INC. | 2001-08-30 | — | — | US | claimed |
| US-6270781-B1 | EFFECTIVE DOSE OF A COMPOUND THAT INHIBITS THE ENZYMATIC PRODUCTION OR RELEASE OF ROMS IN A COSMETICALLY ACCEPTABLE CARRIER ADAPTED FOR TOPICAL DELIVERY AS A COSMETIC PRODUCT | MAXIM PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | claimed |
| WO-2000040240-A1 | METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS | MAXIM PHARMACEUTICAL, INC. (US) | 2000-07-13 | — | — | WO | claimed |
| US-5665802-A | REACTING POLYAMIC ACID WITH A DEHYDRATION-CYCLIZATION AGENT, A CATALYST AND AN ORGANIC PHOSPHORUS COMPOUND; EXCELLENT IN TENSILE STRENGTH AND FLEXIBILITY | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-09-09 | — | — | US | claimed |